| Literature DB >> 31886171 |
Celal Ulasoglu1, Hatice Esin Temiz2, Zuhal Aydan Sağlam2.
Abstract
BACKGROUND AND AIM: As a worldwide infectious bacterium, H. pylori leads to stomach pathologies such as gastritis, peptic ulcer, gastric cancer, MALToma, and various extragastric manifestations. In our study, we aimed to investigate the association between serum vitamin B12 level and cytotoxin-associated gene-A (CagA) seropositivity, which is one of the virulence factors of Helicobacter pylori (H. pylori).Entities:
Mesh:
Substances:
Year: 2019 PMID: 31886171 PMCID: PMC6925818 DOI: 10.1155/2019/1450536
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
H. pylori, CagA, and vitamin B12 status of patients.
| Females, | Males, | Total |
| |
|---|---|---|---|---|
|
| 150 (51.9%) | 139 (48.1%) | 289 (100.0%) |
|
| Age | 43.4 ± 15.6 | 46.5 ± 15.9 | 44.8 ± 15.8 |
|
|
| 117 (78.0%) | 96 (69.1%) | 213 (73.7%) |
|
| CagA (+) (arbU/mL) | 72 (48.0%) | 50 (36.0%) | 122 (42.2%) |
|
| Vitamin B12 (pg/ml) | 292 ± 139 | 288 ± 139 | 292 ± 143 (50–804) | 0.539 |
H. pylori: Helicobacter pylori; CagA: cytotoxin-associated gene-A. +Females versus males. Pearson's chi-square test. Student's t-test.
Helicobacter pylori status and MCV, folate, and B12 levels.
|
|
|
| |
|---|---|---|---|
| MCV (fl) | 86.1 ± 6.0 | 84.9 ± 7.9 | a0.188 |
| Folate (ng/dl) | 8.3 ± 3.2 | 10.9 ± 4.0 |
a0.001 |
| B 12 (median) (min–max) | 276.5 ± 134.0 (256.0) | 338.4 ± 160.8 (299.5) |
d0.003 |
aStudent's t-test. dMann–Whitney U test. p < 0.05. p > 0.01. Min: minimum; Max: maximum; SD: standard deviation; B12: pg/ml; MCV: mean corpuscular volume.
CagA status and MCV, folate, and B12 levels in H. pylori (+) patients.
| CagA-negative ( | CagA-positive ( |
| |
|---|---|---|---|
| MCV (fl) | 86.4 ± 6.1 | 85.9 ± 7.4 | a0.631 |
| Folate (ng/ml) | 7.9 ± 2.80 | 8.6 ± 3.5 | a0.109 |
| B12 (pg/ml) | 318.1 ± 149.1 | 245.6 ± 112.5 |
a0.001 |
aStudent's t-test. p < 0.01. SD: standard deviation; MCV: mean corpuscular volume.
B12 levels in H. pylori (+) patients with and without CagA positivity.
|
| B12 level (mean ± SD) in patients with CagA (+) | B12 level (mean ± SD) in patients with CagA (−) |
| |
|---|---|---|---|---|
| Total | 213 (100%) | 245.5 ± 112.5 | 301.6 ± 146.1 |
a0.003 |
| Lymphocyte (+) | 181 (85.0%) | 243.9 ± 114.8 | 299.8 ± 154.1 |
a
|
| Activation (+) | 133 (62.4%) | 244.2 ± 114.6 | 304.0 ± 153.4 |
a
|
| Metaplasia (+) | 33 (15.5%) | 222.9 ± 109.4 | 273.3 ± 135.0 |
a
|
| Atrophy (+) | 33 (15.5%) | 168.4 ± 60.5 | 285.6 ± 134.3 |
a
|
| Lymphoid follicle(+) | 61 (28.6%) | 234.9 ± 135.5 | 284.9 ± 127.0 |
a0.033 |
aStudent's t-test. B12: pg/ml. p > 0.05. p < 0.05. SD: standard deviation.
CagA serology and relation with histopathological features.
| CagA neg. ( | CagA pos. ( |
| |
|---|---|---|---|
|
|
| ||
| Lymphocyte |
c
| ||
| (−) | 21 (23.1) | 11 (9.0) | |
| (+) | 70 (76.9) | 111 (91.0) | |
|
| |||
| Activation |
b
| ||
| (−) | 44 (48.4) | 36 (29.5) | |
| (+) | 47 (51.6) | 86 (70.5) | |
|
| |||
| Metaplasia |
c
| ||
| (−) | 73 (80.2) | 107 (87.7) | |
| (+) | 18 (19.8) | 15 (12.3) | |
|
| |||
| Atrophy |
c
| ||
| (−) | 80 (87.9) | 100 (82.0) | |
| (+) | 11 (12.1) | 22 (18.0) | |
|
| |||
| Lymphoid follicle |
c
| ||
| (−) | 67 (73.6) | 85 (69.7) | |
| (+) | 24 (26.4) | 37 (30.3) | |
bPearson's chi-square test. cYates Continuity Correction. p < 0.01.